CN丨 EN

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！

Home丨 Contact Us

Search
Register

Copyright:  Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！   京ICP备19006400号-1​     Powered by 300.cn

About Us
Company Overview
Advisors
Qualifications
Memorabilia
Technology
Technology Platform
Products
Intellectual Property
Clinical Programs
Cooperative Partners
Clinical Indications
Clinical Cases
Science
Stem Cells
Stem Cell-Derived Exosomes
Stem Cell Factors
News Center
Company News
Press Release
Contact Us
Contact Us
Videos
Download Center
Online Message

美科

Jiuzhitang丨 Mudanjiang Youbo Pharmaceutical 丨 Beijing Tiantan Hospital丨 No.1 Hospital-Harbin Medical Sciences University丨 Stemedica丨

Links：

Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.

Source:
Release time：
2020/04/20 14:06
Page view

Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.

Previous article:
A team led by Academician Wu Zuze, dubbed as Father of Hematopoietic Stem Cells, visited Jiuzhitang Maker.
Jiuzhitang Maker received fund support from Daxing District Program for Better Development of the Healthcare Industry.
Next article: